Clinical Trials Logo
  1. Home
  2. Male Breast Cancer
  3. NCT01703520

Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).

Male Breast Cancer Clinical Trial

Official title:
Finasteride and Male Breast Cancer - A Register-Based Nested Case-Control Study in Denmark, Finland, Norway, and Sweden

Clinical Trial Summary

The objective of this study is to investigate the potential association between finasteride (MK-0906) exposure and the development of breast cancer in men residing in Denmark, Sweden, Finland, and Norway from data in national registries. The primary hypothesis of this study is that the previously reported increased incidence of male breast cancer among finasteride users is explained by confounding factors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01703520
Study type Observational
Source Organon and Co
Contact
Status Completed
Phase
Start date May 1, 2011
Completion date November 30, 2017
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Phase 2
Completed NCT00096434 - Sorafenib in Treating Patients With Metastatic Breast Cancer Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Active, not recruiting NCT00791037 - Vaccine Therapy in Treating Patients With Stage IV Breast Cancer Phase 1/Phase 2
Completed NCT00559507 - Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00119262 - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer Phase 2
Terminated NCT00095888 - 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer Phase 2
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Terminated NCT00071942 - Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Phase 1
Completed NCT00068588 - GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Phase 2
Recruiting NCT05501704 - ETHAN - ET for Male BC Phase 2
Completed NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Phase 2
Completed NCT02046421 - Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Completed NCT01720602 - Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy N/A
Completed NCT01493310 - Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer Phase 1